"Our top executives from the Paris headquarters have committed significant investments in India. It is difficult to quantify how much investment will come here in the coming years but it will be need based," said Shailesh Ayyangar, managing director, Aventis Pharma, on the sidelines of the launch of SoloStar, its disposable pen for the administration of insulin.
At present, sanofi-aventis has two large manufacturing facilities, one at Ankleswar for active pharmaceutical ingredients (API) and the other in Goa for making tablets.
Manufacture of vaccines and other products from India will be another area of focus for the
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app